Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mild cognitive impairment.

Serge Gauthier1, Barry Reisberg, Michael Zaudig

  • 1McGill Center for Studies in Aging, Douglas Hospital, Montréal, Quebec, Canada. serge.gauthier@mcgill.ca

Lancet (London, England)
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer's disease.

Genome biology·2025
Same author

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies <i>LRRC4C, LHX5-AS1</i> and nominates ancestry-specific loci <i>PTPRK</i> , <i>GRB14</i> , and <i>KIAA0825</i> as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium.

medRxiv : the preprint server for health sciences·2023
Same author

Linking self-perceived cognitive functioning questionnaires using item response theory: The subjective cognitive decline initiative.

Neuropsychology·2023
Same author

Cortical myelin profile variations in healthy aging brain: A T1w/T2w ratio study.

NeuroImage·2022
Same author

Global cognitive trajectory patterns in Alzheimer's disease - CORRIGENDUM.

International psychogeriatrics·2022
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Mild cognitive impairment (MCI) involves cognitive decline not affecting daily life but increases dementia risk. Identifying MCI allows for early intervention and risk factor management, potentially delaying dementia progression.

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is characterized by cognitive decline exceeding age/education expectations, without significant impact on daily activities.
  • Prevalence of MCI in adults over 65 ranges from 3% to 19%, with over half progressing to dementia within 5 years.
  • MCI is recognized as a significant risk state for dementia, highlighting the importance of early detection.

Purpose of the Study:

  • To define mild cognitive impairment (MCI) and its epidemiological prevalence.
  • To explore the progression of MCI to dementia, particularly Alzheimer's disease.
  • To emphasize the potential for secondary prevention through risk factor control in MCI patients.

Main Methods:

  • Review of population-based epidemiological studies on MCI prevalence.

Related Experiment Videos

  • Analysis of longitudinal data on MCI progression to dementia.
  • Examination of the relationship between MCI subtypes and dementia risk.

    • Main Results:

    • MCI affects 3-19% of adults over 65, with significant progression to dementia.
    • The amnestic subtype of MCI shows a high risk of progressing to Alzheimer's disease.
    • Controlling risk factors like systolic hypertension may aid in secondary prevention of dementia.

    Conclusions:

    • Mild cognitive impairment is a critical risk state for dementia, necessitating further research into its subtypes.
    • Early identification of MCI, especially the amnestic subtype, is crucial for potential prodromal intervention for Alzheimer's disease.
    • Continued study of various MCI definitions and subtypes is vital for understanding and preventing dementia.